Cardiovascular diseases (CVD) such as stroke and heart attack remain the leading cause of mortality globally, as per the World Health Organization (WHO), with deaths from CVDs forecast to rise amid an ageing and growing global population.
To meet the challenges of common conditions including stroke and atrial fibrillation (AF), which is estimated to affect over 11 million people in Europe, Boston Scientific has been producing a wealth of data demonstrating the efficacy of its Watchman and Farapulse pulsed-field ablation (PFA) devices for stroke and AF treatment.
Access deeper industry intelligence
Experience unmatched clarity with a single platform that combines unique data, AI, and human expertise.
GlobalData analysis reveals that the global electrophysiology devices market, of which ablation catheters such as Farapulse are a part, is growing at a CAGR of 10.2% and is projected to reach a valuation of almost $25bn in 2035, up from around $9.4bn in 2025.
With a growing body of evidence across AF and stroke prevention from Boston’s studies, including CHAMPION-AF (NCT04394546), VENTURE-AF (NCT01729871), and AVANT GUARD (NCT06096337), Ross Law, editor for Medical Device Network, spoke with Angelo Auricchio, chief medical officer for Boston Scientific’s rhythm management business, EMEA region, to learn more about the rising importance of clinical evidence as a means to help physicians improve patient care.
Listen to the full episode below:
